HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunoenhancement of Recombinant Neisseria meningitides PorB Protein on Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae Genetically Engineered Vaccines.

AbstractBACKGROUND:
Porcine circovirus and Mycoplasma hyopneumoniae can cause respiratory diseases in pigs, which cause serious economic loss in the worldwide pig industry. Currently, these infections are mainly prevented and controlled by vaccination. The new vaccines on the market are mainly composed of subunits and inactivated vaccines but usually have lower antigenicity than traditional live vaccines. Thus, there is an increasing need to develop new adjuvants that can cause rapid and long-lasting immunity to enhance the antigenic efficacy for vaccines. Studies have shown that meningococcal porin PorB can act as a ligand to combine with Toll-like receptors to activate the production of immunological projections and act as a vaccine immunological adjuvant.
OBJECTIVE:
In this article, we expressed and purified the recombinant PorB protein and verified its immunogenicity against porcine circovirus type 2 and Mycoplasma hyopneumoniae genetically engineered vaccine.
METHODS:
In this article, we used prokaryotic expression to express and purify recombinant PorB protein, four different concentrations of PorB protein, Freund's adjuvant with two genetically engineered vaccines were combined with subcutaneous immunization of mice.
RESULTS:
Our study shows that the appropriate dose of the recombinant protein PorB can enhance the levels of humoral and cellular responses induced by two genetically engineered vaccines in a short period of time in mice. The PorB adjuvant group may cause statistically higher antibody titers for both genetically engineered vaccines compared to Freund's commercial adjuvant (P<0.001).
CONCLUSION:
The recombinant protein PorB may be a good candidate adjuvant for improving the protective effect of vaccines against porcine circovirus type 2 and Mycoplasma hyopneumoniae, and the protein can be used for future practical applications.
AuthorsRui Yang, Yu Tao, Gaojian Li, Jian Chen, Jianhong Shu, Yulong He
JournalProtein and peptide letters (Protein Pept Lett) Vol. 26 Issue 10 Pg. 776-784 ( 2019) ISSN: 1875-5305 [Electronic] Netherlands
PMID31208304 (Publication Type: Journal Article)
CopyrightCopyright© Bentham Science Publishers; For any queries, please email at [email protected].
Chemical References
  • Adjuvants, Immunologic
  • Porins
  • Recombinant Proteins
  • Toll-Like Receptors
  • Viral Vaccines
  • porin protein, Neisseria
Topics
  • Adjuvants, Immunologic (pharmacology)
  • Animals
  • Cell Line
  • Cell Proliferation
  • Circovirus (metabolism)
  • Female
  • Lymphocytes (cytology)
  • Meningitis (metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Mycoplasma hyopneumoniae (metabolism)
  • Porins (genetics, metabolism)
  • Recombinant Proteins (genetics, metabolism)
  • Signal Transduction
  • Solubility
  • Swine
  • Toll-Like Receptors (metabolism)
  • Vaccination (methods)
  • Viral Vaccines (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: